Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin, Non-Pharmacologic Treatment of HF
In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Acute Heart Failure, Diet, Exercise, Acute Coronary Syndromes
Keywords: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Hemorrhage, Ventricular Dysfunction, Left, Sodium-Glucose Transporter 2 Inhibitors, Cardiomyopathies, Diet, Heart Failure, Quality of Life, Life Style, Exercise
